HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?
- PMID: 27416577
- PMCID: PMC5016299
- DOI: 10.2450/2016.0027-16
HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?
Figures


Comment on
-
Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries.Virchows Arch A Pathol Anat Histopathol. 1990;417(2):105-11. doi: 10.1007/BF02190527. Virchows Arch A Pathol Anat Histopathol. 1990. PMID: 2142355
-
Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.J Clin Invest. 1987 Aug;80(2):458-65. doi: 10.1172/JCI113093. J Clin Invest. 1987. PMID: 2956279 Free PMC article.
-
Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).Eur J Clin Invest. 1994 Jul;24(7):444-53. doi: 10.1111/j.1365-2362.1994.tb02373.x. Eur J Clin Invest. 1994. PMID: 7957500
-
Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men.Arch Intern Med. 1994 Apr 11;154(7):801-6. Arch Intern Med. 1994. PMID: 8147686
-
In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima.Arterioscler Thromb Vasc Biol. 1997 May;17(5):905-11. doi: 10.1161/01.atv.17.5.905. Arterioscler Thromb Vasc Biol. 1997. PMID: 9157954
-
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study.Circulation. 2008 Jan 15;117(2):176-84. doi: 10.1161/CIRCULATIONAHA.107.715698. Epub 2007 Dec 17. Circulation. 2008. PMID: 18086931
-
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.JAMA. 2009 Jul 22;302(4):412-23. doi: 10.1001/jama.2009.1063. JAMA. 2009. PMID: 19622820 Free PMC article. Review.
-
Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants.J Am Coll Cardiol. 2010 May 11;55(19):2160-7. doi: 10.1016/j.jacc.2009.10.080. J Am Coll Cardiol. 2010. PMID: 20447543
-
Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern.Atheroscler Suppl. 2013 Jan;14(1):39-44. doi: 10.1016/j.atherosclerosissup.2012.10.005. Atheroscler Suppl. 2013. PMID: 23357139
-
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.Atheroscler Suppl. 2013 Jan;14(1):93-9. doi: 10.1016/j.atherosclerosissup.2012.10.015. Atheroscler Suppl. 2013. PMID: 23357149 Clinical Trial.
-
Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.J Am Coll Cardiol. 2013 Mar 19;61(11):1146-56. doi: 10.1016/j.jacc.2012.12.023. Epub 2013 Jan 30. J Am Coll Cardiol. 2013. PMID: 23375930
-
Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?Artif Organs. 2014 Feb;38(2):135-41. doi: 10.1111/aor.12135. Epub 2013 Jul 25. Artif Organs. 2014. PMID: 23889507
-
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.Circulation. 2014 Jan 14;129(2):234-43. doi: 10.1161/CIRCULATIONAHA.113.007012. Epub 2013 Nov 19. Circulation. 2014. PMID: 24255061 Clinical Trial.
References
-
- Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand. 1963;59:369–82. - PubMed
-
- Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol. 1998;82:57–66. - PubMed
-
- Nielsen LB, Gronholdt ML, Schroeder TV, et al. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol. 1997;17:905–11. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources